| scholarly article | Q13442814 |
| P50 | author | Eithan Galun | Q47008783 |
| P2093 | author name string | Abraham Shaked | |
| Kim M Olthoff | |||
| Gideon Zamir | |||
| Andrew E Gelman | |||
| Evelyne Zeira | |||
| Ahmed Eid | |||
| P2860 | cites work | Cellular roles of dna topoisomerases: a molecular perspective | Q22121990 |
| Transcriptional consequences of topoisomerase inhibition | Q24746255 | ||
| DNA topoisomerases | Q29619953 | ||
| Combination gene therapy for liver metastasis of colon carcinoma in vivo | Q34480736 | ||
| Molecular therapies for colorectal cancer metastatic to the liver | Q34625622 | ||
| Intravascular adenoviral agents in cancer patients: lessons from clinical trials | Q35043094 | ||
| Adenoviral vectors: systemic delivery and tumor targeting | Q35043111 | ||
| Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy | Q35232341 | ||
| An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. | Q35748116 | ||
| Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function | Q35833642 | ||
| Human DNA topoisomerase I: relaxation, roles, and damage control | Q36097816 | ||
| Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development | Q36431807 | ||
| Adenovirus infection elevates levels of cellular topoisomerase I. | Q37683943 | ||
| Expression of the type I DNA topoisomerase gene in adenovirus-5 infected human cells | Q40514177 | ||
| Eukaryotic DNA topoisomerases I. | Q40540261 | ||
| Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. | Q40594608 | ||
| Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin | Q40851011 | ||
| Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials | Q42285715 | ||
| DNA topoisomerase I is involved in both repression and activation of transcription | Q42508509 | ||
| Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription | Q42529109 | ||
| Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle | Q43687076 | ||
| Mitochondrial biogenesis during skeletal muscle regeneration | Q43908131 | ||
| Imaging transgene expression in live animals | Q45198958 | ||
| Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages | Q45877053 | ||
| Adenovirus-mediated in vivo gene transfer and expression in normal rat liver | Q45878870 | ||
| Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. | Q45880303 | ||
| Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. | Q52544982 | ||
| A multitasking oncolytic adenovirus vector | Q64377757 | ||
| TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression | Q64379841 | ||
| Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects | Q73797210 | ||
| Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme | Q77333600 | ||
| P433 | issue | 4 | |
| P921 | main subject | Adenoviridae | Q193447 |
| P304 | page(s) | 772-781 | |
| P577 | publication date | 2007-02-13 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression | |
| P478 | volume | 15 |
Search more.